Pharmaco-epigenomics: Discovering therapeutic approaches and biomarkers for cancer therapy

Heredity

Volumn 105, Issue 1, 2010, Pages 152-160

  Claes, B ^a   Buysschaert, I ^a   Lambrechts, D ^a  

^a Vesalius Research Center   (Belgium)

Author keywords

Angiogenesis; Biomarker; Cancer therapy; DNA methylation; Histone modification; Pharmaco epigenomics

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

BIOMARKER; CANCER; DISEASE TREATMENT; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC MARKER; INHIBITOR; METHYLATION; PROTEIN; TUMOR;

CHEMISTRY; GENETIC EPIGENESIS; GENETICS; HUMAN; NEOPLASM; REVIEW; MEDICINAL CHEMISTRY; NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHEMISTRY, PHARMACEUTICAL; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 77953807423     PISSN: 0018067X     EISSN: 13652540     Source Type: Journal    
DOI: 10.1038/hdy.2010.42     Document Type: Review

References (91)

1. Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF et al. (2006). Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA 103: 8822-8827. (Pubitemid 43878103)
2. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J et al. (2003). Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J 22: 6335-6345.
3. Baylin SB (2004). Reversal of gene silencing as a therapeutic target for cancer-roles for DNA methylation and its interdigitation with chromatin. Novartis Found Symp 259: 226-233;discussion 234-237, 285-288.
4. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E et al. (1998). Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95: 11891-11896.
5. Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, Futscher BW et al. (2007). Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 26: 2791-2798.
6. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE (2006). Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 8: R38.
7. Buysschaert I, Schmidt T, Roncal C, Carmeliet P, Lambrechts D (2008). Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. J Cell Mol Med 12 (6B): 2533-2551.
8. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M et al. (2001). Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 7: 2727-2730.
9. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107.
10. Carmeliet P (2005). Angiogenesis in life, disease and medicine. Nature 438: 932-936.
11. Carr BI, Rahbar S, Asmeron Y, Riggs A, Winberg CD (1988). Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br J Cancer 57: 395-402.
12. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE et al. (2003). Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95: 399-409.
13. Chou CW, Chen CC (2008). HDAC inhibition upregulates the expression of angiostatic ADAMTS1. FEBS Lett 582: 4059-4065.
14. Dai Y, Rahmani M, Dent P, Grant S (2005). Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NFkappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 25: 5429-5444.
15. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, Clausse N et al. (2002). Histone deacetylases inhibitors as antiangiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436.
16. Duan H, Heckman CA, Boxer LM (2005). Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25: 1608-1619.
17. Eden A, Gaudet F, Waghmare A, Jaenisch R (2003). Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455.
18. Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I et al. (2009). Global levels of histone modifications predict prostate cancer recurrence. Prostate 70: 61-69.
19. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG (1998). Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58: 4515-4518.
20. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B et al. (2002). Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94: 26-32.
21. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha Vet al. (2000). Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354.
22. Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T et al. (2006). Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 12(11 Part 1): 3306-3310.
23. Feinberg AP (2007). Phenotypic plasticity and the epigenetics of human disease. Nature 447: 433-440.
24. Feinberg AP, Tycko B (2004). The history of cancer epigenetics. Nat Rev Cancer 4: 143-153.
25. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
26. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400.
27. Geiman TM, Robertson KD (2002). Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J Cell Biochem 87: 117-125.
28. Gluckman PD, Hanson MA, Cooper C, Thornburg KL (2008). Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 359: 61-73.
29. Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K et al. (2006). Phase I trial of sequential low-dose 5-aza-20-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12: 4619-4627.
30. Hackanson B, Robbel C, Wijermans P, Lubbert M (2005). In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Ann Hematol 84(Suppl 1): 32-38.
31. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell 100: 57-70.
32. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
33. Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH et al. (2006a). Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 66: 10770-10777.
34. Hellebrekers DM, Jair KW, Vire E, Eguchi S, Hoebers NT, Fraga MF et al. (2006b). Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 5: 467-475.
35. Hellebrekers DM, Melotte V, Vire E, Langenkamp E, Molema G, Fuks F et al. (2007). Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 67: 4138-4148.
36. Herman JG, Baylin SB (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054.
37. Hinshelwood RA, Huschtscha LI, Melki J, Stirzaker C, Abdipranoto A, Vissel B et al. (2007). Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis. Cancer Res 67: 11517-11527.
38. Hu CJ, Chen SD, Yang DI, Lin TN, Chen CM, Huang TH et al. (2006). Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab 26: 1519-1526.
39. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R (1997). Mutagenicity of 5-aza-20-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci USA 94: 4681-4685.
40. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG et al. (2001). Quantitation of GSTP1 methylation in nonneoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 93: 1747-1752.
41. Jones PA, Baylin SB (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
42. Jones PA, Baylin SB (2007). The epigenomics of cancer. Cell 128: 683-692.
43. Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K (2004). Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23: 6304-6315.
44. Karpf AR, Peterson PW, Rawlins JT, Dalley BK, Yang Q, Albertsen H et al. (1999). Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc Natl Acad Sci USA 96: 14007-14012.
45. Kerbel RS (2008). Tumor angiogenesis. N Engl J Med 358: 2039-2049.
46. Khan O, La Thangue NB (2008). Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol 5: 714-726.
47. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW et al. (2001). Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443.
48. Kouzarides T (2007). Chromatin modifications and their function. Cell 128: 693-705.
49. Lee MN, Tseng RC, Hsu HS, Chen JY, Tzao C, Ho WL et al. (2007). Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 13: 832-838.
50. Li Q, Ahuja N, Burger PC, Issa JP (1999). Methylation and silencing of the thrombospondin-1 promoter in human cancer. Oncogene 18: 3284-3289.
51. Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T (2002). Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-20-deoxycytidine. Cancer Res 62: 961-966.
52. Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA et al. (2009). N-Myc downstreamregulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst 101: 916-927.
53. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA et al. (2004). Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520-527.
54. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J (1997). Pilot phase I-II study on 5-aza-20-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8: 358-368.
55. Moore M, Ullman C (2003). Recent developments in the engineering of zinc finger proteins. Brief Funct Genomic Proteomic 1: 342-355.
56. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E et al. (2003). DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63: 7641-7645.
57. Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL et al. (2005). Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 11: 4912-4922.
58. Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE (2006). Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther 5: 1967-1974.
59. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G et al. (2002). Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-20-deoxycytidine. Cancer Res 62: 6456-6461.
60. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F (2009). Implications for KRAS status and EGFRtargeted therapies in metastatic CRC. Nat Rev Clin Oncol 6: 519-527.
61. Pharoah PD, Day NE, Caldas C (1999). Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80: 1968-1973.
62. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N et al. (2006). Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 24: 3771-3779.
63. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K et al. (2006). Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 98: 756-762.
64. Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F et al. (2005). p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep 13: 1139-1144.
65. Rojas A, Meherem S, Kim YH, Washington MK, Willis JE, Markowitz SD et al. (2008). The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer. Int J Cancer 123: 14-21.
66. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U et al. (2002). Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91: 837-844.
67. Rossig L, Urbich C, Bruhl T, Dernbach E, Heeschen C, Chavakis E et al. (2005). Histone deacetylase activity is essential for the expression of HoxA9 and for endothelial commitment of progenitor cells. J Exp Med 201: 1825-1835.
68. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA et al. (2006). Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatinmodifying drugs in human cancer cells. Cancer Cell 9: 435-443.
69. Sasaki H, Matsui Y (2008). Epigenetic events in mammalian germ-cell development: reprogramming and beyond. Nat Rev Genet 9: 129-140.
70. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT et al. (2007). Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol 25: 64-69.
71. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF et al. (2006). Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12: 5777-5785.
72. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M et al. (2005). Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-1266.
73. Shaker S, Bernstein M, Momparler LF, Momparler RL (2003). Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-20-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 27: 437-444.
74. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G et al. (2005). Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 25: 5404-5416.
75. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. (2002). Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20: 2429-2440. (Pubitemid 34525728)
76. Silverman LR, Mufti GJ (2005). Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol 2(Suppl 1): S12-S23.
77. Smith LT, Otterson GA, Plass C (2007). Unraveling the epigenetic code of cancer for therapy. Trends Genet 23: 449-456.
78. Sotiriou C, Pusztai L (2009). Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800.
79. Strahl BD, Allis CD (2000). The language of covalent histone modifications. Nature 403: 41-45.
80. Strathdee G, MacKean MJ, Illand M, Brown R (1999). A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335-2341.
81. Stratton MR, Campbell PJ, Futreal PA (2009). The cancer genome. Nature 458: 719-724.
82. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP et al. (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 31: 141-149.
83. Szyf M (2004). Toward a discipline of pharmacoepigenomics. Curr Pharmacogenomics 2: 357-377.
84. Tapia T, Smalley SV, Kohen P, Munoz A, Solis LM, Corvalan A et al. (2008). Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics 3: 157-163.
85. Verbisck NV, Costa ET, Costa FF, Cavalher FP, Costa MD, Muras A et al. (2009). ADAM23 negatively modulates alpha(v)beta- (3) integrin activation during metastasis. Cancer Res 69: 5546-5552.
86. Wettergren Y, Odin E, Nilsson S, Carlsson G, Gustavsson B (2008). p16INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer. Mol Med 14: 412-421.
87. Wilson AS, Power BE, Molloy PL (2007). DNA hypomethylation and human diseases. Biochim Biophys Acta 1775: 138-162.
88. Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP (2003). Comment on 'Chromosomal instability and tumors promoted by DNA hypomethylation' and 'Induction of tumors in nice by genomic hypomethylation'. Science 302: 1153; author reply 1153.
89. Yang D, Thangaraju M, Greeneltch K, Browning DD, Schoenlein PV, Tamura Tet al. (2007). Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res 67: 3301-3309.
90. Yoo CB, Jones PA (2006). Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
91. Young PP, Vaughan DE, Hatzopoulos AK (2007). Biologic properties of endothelial progenitor cells and their potential for cell therapy. Prog Cardiovasc Dis 49: 421-429.